Only a small fraction (~10%) of the 98 predicted off-targets were experimental tested in this study. However, as we did observe active binding on 3 distinct targets, this study suggests that there might be other interactions among the list of predicted targets. Thus, further testing might help to elucidate the molecular mechanisms of JAK inhibitors, and open the door for improved understanding of the safety concerns and repurposing in other conditions (e.g., in neurodegenerative diseases, diabetes and viral infections).